Prediction Models for Severe Manifestations and Mortality due to COVID-19: A Rapid Systematic Review

Jamie L. Miller

MD Candidate

University of Iowa Carver College of Medicine

Masafumi Tada, MD

Department of Health Promotion and Human Behavior

Kyoto University Graduate School of Medicine / School of Public Health

Michihiko Goto MD MSCI

Division of Infectious Diseases

Department of Internal Medicine

University of Iowa Carver College of Medicine

Nicholas Mohr

Department of Emergency Medicine

Department of Anesthesia

Department of Epidemiology

University of Iowa Carver College of Medicine

Sangil Lee MD, MS

Clinical Associate Professor

Department of Emergency Medicine

The University of Iowa Carver College of Medicine

Acknowledgement

We thank the assistance to generate search strategy and identifying the literature from Jennifer Deberg, MLS, and Hans R House, MD, at the University of Iowa.

ABSTRACT

Background

Throughout 2020, the coronavirus disease 2019 (COVID-19) has become a threat to public health on national and global level. There has been an immediate need for research to understand

the clinical signs and symptoms of COVID-19 that can help predict deterioration including mechanical ventilation, organ support, and death. Studies thus far have addressed the epidemiology of the disease, common presentations, and susceptibility to acquisition and transmission of the virus; however, an accurate prognostic model for severe manifestations of COVID-19 is still needed because of the limited healthcare resources available.

Objective

This systematic review aims to evaluate published reports of prediction models for severe illnesses caused COVID-19.

Methods

Searches were developed by the primary author and a medical librarian using an iterative process of gathering and evaluating terms. Comprehensive strategies, including both index and keyword methods, were devised for PubMed and EMBASE. The data of confirmed COVID-19 patients from randomized control studies, cohort studies, and case-control studies published between January 2020 and July 2020 were retrieved. Studies were independently assessed for risk of bias and applicability using the Prediction Model Risk Of Bias Assessment Tool (PROBAST). We collected study type, setting, sample size, type of validation, and outcome including intubation, ventilation, any other type of organ support, or death. The combination of the prediction model, scoring system, performance of predictive models, and geographic locations were summarized.

Results

A primary review found 292 articles relevant based on title and abstract. After further review, 246 were excluded based on the defined inclusion and exclusion criteria. Forty-six articles were included in the qualitative analysis. Inter observer agreement on inclusion was 0.86 (95% confidence interval: 0.79 - 0.93). When the PROBAST tool was applied, 44 of the 46 articles were identified to have high or unclear risk of bias, or high or unclear concern for applicability. Two studies reported prediction models, 4C Mortality Score from hospital data and QCOVID from general public data from UK, and were rated as low risk of bias and low concerns for applicability.

Conclusion

Several prognostic models are reported in the literature, but many of them had concerning risks of biases and applicability. For most of the studies, caution is needed before use, as many of

them will require external validation before dissemination. However, two articles were found to have low risk of bias and low applicability can be useful tools.

INTRODUCTION

Background

COVID-19 is the disease caused by SARS-CoV-2 that emerged in China in December 2019.¹ Throughout 2020, COVID-19 has become an increasing threat to public health on national and global level.² There has been an immediate need for research to help predict the clinical deterioration including death, mechanical ventilation, and organ support.³ A precise risk stratification of individuals with COVID-19 enables allocation of appropriate resources such as hospitalization, intensive care admission, ventilatory support, and antiviral therapy.⁴ As we start to understand the unique nature of this infection, an accurate risk stratification tool is urgently needed.

Studies thus far have addressed the epidemiology of the disease, common presentations, and susceptibility to disease acquisition and transmission of the virus.^{5,6,7} However, the short- and long-term implications of developing severe illnesses caused by COVID-19 is still widely unknown. Many studies with methodological shortcomings are published to facilitate the dissemination of rapidly evolving science of COVID-19.^{8,9} The quality of prediction models related to COVID-19 also suffered, as many studies did not have adequate validation steps after models were developed.⁹ The purpose of this review is to consolidate published data on validated predictive models of severe illnesses caused by COVID-19. We undertook a rapid systematic review following the format given by the King et al¹⁰

Goals of this investigation

The goal of our review was to collectively evaluate published findings of prediction models for severe illness caused by COVID-19 to inform healthcare providers and the general population of the existing evidence in the midst of the pandemic.

METHODS

The review protocol was registered to PROSPERO (registration number CRD42020201484). Our study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analyses

guidelines for systematic reviews and was performed in accordance with best-practice guidelines (PRISMA).¹¹

Search strategies were developed with the assistance of a health sciences librarian with expertise in systematic reviews. Searches were developed by the primary author and librarian using an iterative process of gathering and evaluating terms. Searches were finalized in July 2020. Comprehensive strategies, including both index and keyword methods, were devised for PubMed and EMBASE. In order to maximize sensitivity, no pre-established database filters were used other than English language. We also screened references of articles identified by these systematic search strategies to look for any additional records potentially useful for the aim of this review. Lastly, we examined additional articles through a referral from investigators and online journal updates. The completed PubMed strategy is shown in Supplemental file 1. PubMed Strategy was then adapted for EMBASE and is available upon request. The last search was conducted on 7/27/2020.

We included studies of randomized controlled trials, cohort studies, and case-control studies that discuss the possible short-term and long-term consequences of contracting COVID-19 in any clinical setting. All studies were considered regardless of publication status (preprint or peer review manuscript), as long as those are included to PubMed or EMBASE. The definition of positive COVID-19 included a positive nasopharyngeal or oropharyngeal swab for COVID-19 by polymerase-chain reaction (PCR) or antigen tests, serological test for COVID-19, or those who were clinically diagnosed as COVID-19 based on clinical presentation and epidemiologic information. Outcomes included intubation, mechanical ventilation, any other type of organ support (for example, hemodialysis), and/or death. We included studies that developed and validated a multivariable model or scoring system, based on individual participant level data, to predict any COVID-19 related outcome or externally validated a known scoring system. We excluded review articles, case reports, editorials, and comments. Studies reporting the predictive ability of a single test, for example, a study only focused on the prognostic value of lactate dehydrogenase (LDH), were excluded from the review, since we were primarily interested in the combination of test results with any internal or external validation. Epidemiological studies that

aimed to model disease transmission or diagnostic test accuracy, and predictor finding studies were also excluded.

Data Collection and Processing

Titles, abstracts, and full texts were screened in duplicate for eligibility by independent reviewers (JM and SL), and discrepancies were resolved through discussion moderated by the third reviewer (MG). The reasons for any exclusions were recorded for those that required full article review.

Two investigators (JM, MT) independently extracted data from the included studies. The investigators underwent initial training and extracted data into a predesigned data collection form. The following information was abstracted: author, year, setting, outcome, predictors in final model, sample size for development set, type of validation, sample size, performance, and geographical region.

When data were missing or ambiguous, we contacted the authors for clarification. Studies were independently assessed for risk of bias by two investigators (JM, MT) using the Prediction Model Risk Of Bias Assessment Tool (PROBAST) tool. Any discrepancies were resolved by consensus.

Primary Data Analysis

A narrative synthesis of the characteristics of the included studies, including the outcomes, sample size for development and validation, type of case ascertainment, relationship between the final model, and the development of severe illnesses, were summarized in a table. We listed risk of bias and applicability using the PROBAST¹² tool. To maximize the synthesis of results, we reported the studies based on the low risk of bias, low concern for applicability, and geographical location for future use.

RESULTS

Study selection

We included a total of 292 of 3399 articles based on the title and abstract. Then, we included a total of 42 out of 292 during the secondary full text screening up to July 2020. We identified an additional four articles from an investigator, online journal update, and references. The details of the selection process are listed in Figure 1. Overall, kappa was 0.86 (95% 0.79 - 0.93) between two reviewers.

Characteristics of studies

A total of 41 (89%) articles were identified from peer review journals and 5 (11%) were from preprints (Figure 1). The majority of studies (n=25, 53%) were published in China, 9 studies (19%) in the U.S. and 7 (15%) were published in Europe. (Table 1).

There were 38 (82%) retrospective cohort studies, and four (9%) prospective cohort studies, and four (9%) retrospective and prospective studies. The majority (n=25, 54%) were conducted at a single institution, 21 studies (46%) were conducted at two or more sites. There were two studies that were conducted in multiple nations.^{12, 13} The total sample was 8,621,479 patients, and the mean sample size used for model derivation in the 46 articles was 187,423 (range 66-8,256,158).

Critical appraisal of quality

Next, using the PROBAST, we evaluated the risk of bias for each study and concern for applicability using the low, high, or unclear categories. The articles where the PROBAST tool did not apply were categorized as not applicable.

The PROBAST composite scores of the 46 articles, at the domain and item level, are presented in Figure 2. The overall risk of bias was low in four (9%) studies, high in 34 (74%) studies, and unclear in eight (17%) studies. The overall concern for applicability was low in 22 (48%) studies, high in 17 (37%) studies, and unclear in seven (15%) studies. (Figure 2)

The lowest risk of bias was seen in the participants domain (29 studies with low risks of bias, 63%), and highest risk of bias was seen in the analysis domain (32 studies with high risks of bias, 70%). The lowest concern for applicability was seen in the participants domain (38 studies with low concern, 83%), and the highest risk of concern for applicability was seen in the outcome

domain (high concern, n=16, 35%). When the PROBAST evaluation was stratified to multi-site studies, there were increase in the overall applicability (Figure 3).

Two studies (4.3%) reported the prediction from images and seven (15%) studies reported the combinations of clinical data and images. These studies included chest X-ray and Computed Tomography (CT findings) either by itself or in conjunction with clinical data. The predictive ability of these models (AUC) reached 0.8 to 0.9, but most of these studies had a high or unclear risk of bias, which was similar to the recent review reported by Wynants et al.¹¹

Overall, we identified two studies with a low risk of bias and low concern for applicability based on the PROBAST tool, which were Clift et al. and Knight et al. (Table 3)^{13,15}

Individual Study Characteristics

Detailed characteristics of each of the 46 studies are presented in Table 1. Importantly, 5 (11%) of studies used external validation of the existing clinical prediction scores, and 41 (89%) of studies developed a new model and internally or externally validated it. Two studies (4.3%) reported the prediction from images and 7 (15%) reported the combinations of clinical data and images.

Synthesis of Results

Based on the PROBAST tools, we listed the studies with low risk of bias, low concerns for applicability, and predictive ability, metrics, setting, geographic location, and the link to an online calculator in Table 2.

Two studies were found to have low risk of bias and low concern for applicability (Table 2), and therefore warrant further description. Clift et al.¹⁵ developed a prediction model using various risk factors including age, sex, ethnicity, BMI, postal (zip) code, housing, and comorbidity. It was conducted in the general population in the UK during the first wave, and the absolute risk depends on the incidence in the UK at the time. An example shows a 55-year-old black African man with type 2 diabetes, a body mass index of 27.7, and no other risk factors. His absolute risk of catching and dying from covid-19 over the 90 day period is 0.1095% (or 1 in 913). His relative risk compared with a white man aged 55 years and a body mass index of 25 is 10.84.

The model shows that he is in the top 10% of the population at the highest risk. Knight et al.¹³ developed and validated a risk score based on common parameters that are available at hospital admission. This included factors such as age, sex, comorbidity, respiratory rate, SpO₂, GSC, BUN, and CRP. The study was on the inpatient population, and study findings, particularly the probability of mortality, could easily be adapted for use outside the UK. The study reported the low, intermediate, high, and very high risk for mortality based on predictors. For example, patients in the intermediate-risk group (score 4-8, 21.9%) had a mortality rate of 9.9%. Patients in the high-risk group (score 9-14, n=11 664, 52.2%) had a mortality rate of 31.4%.¹³ However, one should account for differences in the criteria for admission and the quality of care (Table 2).

DISCUSSION

This systematic review identified a total of 46 articles that predicted severe COVID-19 in the literature. The majority of articles are from China, Europe, and North America where COVID-19 hit the hardest. These prediction models are focused on prognosticating patients with COVID-19. Overall, models reported the validation AUC from 0.54 to 0.98, but risk of bias was unclear or high for many studies, likely due to limited transparency on the predictor and outcome assessment, limited number of samples and outcomes. Many of these studies are retrospective studies and from early in the pandemic; most of them are limited due to the event rate and unclear case and outcomes definitions. Sample size was variable throughout studies, and lastly, analysis domain, such as overfitting were often seen as the limitation. These are commonly identified problems with building prediction models, and likely causes overfitting.¹⁶

Although many of the studies are reported out of urgency, several of them did not seem to follow TRIPOD guidelines,¹⁷ which likely contributed to the overall risk of bias for the included studies. After review of the current literature, our impression is that many of the reported prediction models have high/unclear risk of bias, thus it is not recommended that any particular tool should be used until further external validation is completed, unless the risk of bias is low.

This review identified several implications for potential application of these prediction models in the appropriate clinical settings. As stated earlier, there are 41 studies that reported original models during the pandemic, and four studies^{24,32,41,45} that reported the external validation

models from the severity prediction models which existed before the COVID-19. Clift et al., Knight et al., reported the models that were developed from nationwide data which enabled robust re-sampling methods to minimize overfitting.^{13,15} We conclude that two of them^{13,15} can be useful tools (Table 3).

Clift et al.¹⁵ reported population-based risk algorithm in the UK, showing high levels of discrimination for deaths and hospital admissions due to covid-19. The absolute risks presented, however, will change over time in line with the prevailing SARS-CoV-2 infection rate and the extent of social distancing measures in place, so they should be interpreted with caution. Because the incidence of COVID19 varies widely according to region and timing and therefore generalizability of the absolute risk is limited. The authors reported relative risk, which is less sensitive to incidence, so that it can be used in other countries. Knight et al.¹³ reported mortality estimates from hospitalized adults in the UK. The authors categorized the risk group into very low, low, intermediate, high, and very high for in-hospital mortality. This study took place when the first wave hit the UK, and to account for concerns regarding the level of care at the time of the pandemic, the authors employed temporal validation. The prediction model could be used to determine the level of care, such as discharge or hospitalization and escalation of care after hospitalization.

Strength and Limitations

Our review used a clear inclusion and exclusion criteria, which likely led to almost perfect agreement between two reviewers. Furthermore, the use of PROBAST strengthened our review, as this tool enabled accurate evaluation of risk of bias and applicability for each of the included studies.

There are several limitations. First, we used only two databases to identify the literature, which is less than we need for a traditional systematic review. We undertook this review to disseminate a rapidly progressing science of COVID-19 for healthcare providers. Second, our search was completed in July 2020, but this review required additional time to train reviewers to use the PROBAST tool to evaluate each article. Due to the rapid development of COVID-19 pandemic, it is important to note the gap between our search timeline and the current status at the time of

article publication. Third, variables and types of prediction models were highly variable among studies, and it was infeasible to conduct meta-analysis or meta-regression, as we specified in the protocol. Our aim was to systematically curate the current state of scientific knowledge to predict severe COVID-19, and we argue that our findings are still informative to healthcare providers without a pooling of results. Fourth, we were primarily interested in multivariable models, which may not have captured innovative studies focused on one predictive marker. Lastly, the volume of literature related to this topic area was a challenge, particularly for preprint articles. Due to concerns with feasibility, database search for preprints were limited to the records included in the mentioned databases.

CONCLUSION

Our review identified several prognostic models for COVID-19, and they showed various discriminative performances. The risk of bias was overall high or unclear for most of the studies, and the risk of bias was highest for the analysis domain. Concern for applicability was low for the majority of included studies. Thus, it is possible that most studies are prone to bias and require external validation before dissemination. The use of prediction models for severe COVID-19 cases requires caution since risk of bias is not negligible. We reported two studies that had a low risk of bias and low concern for applicability, one from a general public population and hospital setting in the UK.

Figure 1. PRISMA diagram

Figure 2. Risk of Bias and Concern for Applicability

Figure 3. Risk of Bias and Concern for Applicability Restricted to Multi-sites

Table 1. Data Summary

Table 2. A List of Studies with Low Risk of Bias and Low Concern for Applicability

REFERENCES

1. Liu, N.-N. T., Jing-Cong; Li, Jingquan; Li, Shenghui; Cai, Yong; Wang, Hui. (2020). COVID-19 Pandemic: Experiences in China and Implications for its Prevention and Treatment Worldwide. *Current Cancer Drug Targets*, 20(6), 410-416. doi:10.2174/1568009620666200414151419
2. Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. *Acta Biomed*, 91(1), 157-160. doi:10.23750/abm.v91i1.9397
3. Zhang, C., Qin, L., Li, K., Wang, Q., Zhao, Y., Xu, B., . . . Zhang, Y. (2020). A Novel Scoring System for Prediction of Disease Severity in COVID-19. *Front Cell Infect Microbiol*, 10, 318. doi:10.3389/fcimb.2020.00318
4. Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 Vaccines at Pandemic Speed. *N Engl J Med*, 382(21), 1969-1973. doi:10.1056/NEJMp2005630
5. Fu, L., Wang, B., Yuan, T., Chen, X., Ao, Y., Fitzpatrick, T., . . . Zou, H. (2020). Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect*, 80(6), 656-665. doi:10.1016/j.jinf.2020.03.041
6. Ge, H., Wang, X., Yuan, X., Xiao, G., Wang, C., Deng, T., . . . Xiao, X. (2020). The epidemiology and clinical information about COVID-19. *Eur J Clin Microbiol Infect Dis*, 39(6), 1011-1019. doi:10.1007/s10096-020-03874-z
7. Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. *Clin Chim Acta*, 508, 254-266. doi:10.1016/j.cca.2020.05.044
8. Mehra, M. R., Ruschitzka, F., & Patel, A. N. (2020). Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet*, 395(10240). doi:10.1016/s0140-6736(20)31324-6
9. Wynants, L., Van Calster, B., Collins, G. S., Riley, R. D., Heinze, G., Schuit, E., . . . van Smeden, M. (2020). Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. *Bmj*, 369, m1328. doi:10.1136/bmj.m1328

10. B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. *J Clin Epidemiol*. 2020 Oct 15;130:13-22. doi: 10.1016/j.jclinepi.2020.10.007
11. Alessandro Liberati, M., DrPH; Douglas G. Altman, DSc; Jennifer Tetzlaff, BSc; Cynthia Mulrow, MD, MSc; Peter C. Gøtzsche, MD, DrMedSci, MSc; John P.A. Ioannidis, MD; Mike Clarke, BA, DPhil; P.J. Devereaux, MD, BSc, PhD; Jos Kleijnen, MD, PhD; and David Moher, PhD. (2009). The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *Annals of Internal Medicine*, 151(4), 65-94.
12. Wolff, R. F., Moons, K. G. M., Riley, R. D., Whiting, P. F., Westwood, M., Collins, G. S., Groupdagger, P. (2019). PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Ann Intern Med*, 170(1), 51-58. doi:10.7326/M18-1376
13. Knight, S. R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T. M., . . . investigators, I. C. (2020). Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *Bmj*, 370, m3339. doi:10.1136/bmj.m3339
14. Wu, G., Yang, P., Xie, Y., Woodruff, H. C., Rao, X., Guiot, J., . . . Lambin, P. (2020). Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. *Eur Respir J*, 56(2). doi:10.1183/13993003.01104-2020
15. Clift, A. K., Coupland, C. A. C., Keogh, R. H., Diaz-Ordaz, K., Williamson, E., Harrison, E. M., . . . Hippisley-Cox, J. (2020). Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *Bmj*, 371, m3731. doi:10.1136/bmj.m3731
16. Salomón Wollenstein-Betech, C. G. C., Ioannis Ch. Paschalidis. (2020). PERSONALIZED PREDICTIVE MODELS FOR SYMPTOMATIC COVID-19 PATIENTS USING BASIC PRECONDITIONS: Hospitalizations, Mortality, and the Need for an ICU or Ventilator. doi:10.1101/2020.05.03.20089813.

17. Riley, R. D., Ensor, J., Snell, K. I. E., Harrell, F. E., Jr., Martin, G. P., Reitsma, J. B., . . . van Smeden, M. (2020). Calculating the sample size required for developing a clinical prediction model. *Bmj*, 368, m441. doi:10.1136/bmj.m441
18. Moons, K. G., Altman, D. G., Reitsma, J. B., Ioannidis, J. P., Macaskill, P., Steyerberg, E. W., . . . Collins, G. S. (2015). Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med*, 162(1), W1-73. doi:10.7326/M14-0698
19. Al-Najjar, H., & Al-Rousan, N. A classifier prediction model to predict the status of Coronavirus COVID-19 patients in South Korea. *Eur Rev Med Pharmacol Sci*, 24(6), 3400-3403.
20. Bae, J., Kapse, S., Singh, G., Phatak, T., Green, J., Madan, N., & Prasanna, P. Predicting Mechanical Ventilation Requirement and Mortality in COVID-19 using Radiomics and Deep Learning on Chest Radiographs: A Multi-Institutional Study. *ArXiv*.
21. Bahl, A., Van Baalen, M. N., Ortiz, L., Chen, N. W., Todd, C., Milad, M., . . . Qu, L. (2020). Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. *Intern Emerg Med*, 15(8), 1485-1499. doi:10.1007/s11739-020-02509-7
22. Bello-Chavolla, O. Y., Bahena-López, J. P., Antonio-Villa, N. E., Vargas-Vázquez, A., González-Díaz, A., Márquez-Salinas, A., . . . Aguilar-Salinas, C. A. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *J Clin Endocrinol Metab*, 105(8).
23. Bi, X., Su, Z., Yan, H., Du, J., Wang, J., Chen, L., . . . Li, J. Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count. *Platelets*, 31(5), 674-679.
24. Borghesi, A., Zigliani, A., Golemi, S., Carapella, N., Maculotti, P., Farina, D., & Maroldi, R. (2020). Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302 patients from Italy. *Int J Infect Dis*, 96, 291-293. doi:10.1016/j.ijid.2020.05.021
25. Chen, R., Liang, W., Jiang, M., Guan, W., Zhan, C., Wang, T., . . . Zhong, N. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*, 158(1), 97-105.

26. Cheng, A., Hu, L., Wang, Y., Huang, L., Zhao, L., Zhang, C., . . . Liu, Q. Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients. *Int J Antimicrob Agents*, 106110.
27. Cheng, F. Y., Joshi, H., on, P., Freeman, R., Reich, D. L., Mazumdar, M., . . . Kia, A. Using Machine Learning to Predict ICU Transfer in Hospitalized COVID-19 Patients. *J Clin Med*, 9(6).
28. Dong, Y. M., Sun, J., Li, Y. X., Chen, Q., Liu, Q. Q., Sun, Z., . . . Ye, D. W. (2020). Development and Validation of a Nomogram for Assessing Survival in Patients with COVID-19 Pneumonia. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Retrieved from <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L632321602> <http://dx.doi.org/10.1093/cid/ciaa963>
29. Galloway, J. B., Norton, S., Barker, R. D., Brookes, A., Carey, I., Clarke, B. D., . . . Cantle, F. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. *J Infect*, 81(2), 282-288.
30. Gong, J., Ou, J., Qiu, X., Jie, Y., Chen, Y., Yuan, L., . . . Hu, B. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. *Clin Infect Dis*.
31. Haimovich, A. D., Ravindra, N. G., Stoytchev, S., Young, H. P., Wilson, F. P., van Dijk, D., . . . Taylor, R. A. (2020). Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. *Ann Emerg Med*, 76(4), 442-453. doi:10.1016/j.annemergmed.2020.07.022
32. Hu, H., Yao, N., & Qiu, Y. (2020). Comparing rapid scoring systems in mortality prediction of critical ill patients with novel coronavirus disease. *Academic Emergency Medicine*. Retrieved from <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2004789961> <http://dx.doi.org/10.1111/acem.13992>
33. Jang, J. G., Hur, J., Hong, K. S., Lee, W., & Ahn, J. H. (2020). Prognostic Accuracy of the SIRS, qSOFA, and NEWS for Early Detection of Clinical Deterioration in SARS-CoV-2 Infected Patients. *J Korean Med Sci*, 35(25), e234. doi:10.3346/jkms.2020.35.e234

34. Ji, D., Zhang, D., Xu, J., Chen, Z., Yang, T., Zhao, P., . . . Qin, E. (2020). Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. *Clin Infect Dis*, 71(6), 1393-1399. doi:10.1093/cid/ciaa414
35. Li, M., Nishanth Thumbavanam Arun, Mishka Gidwani, BS, Ken Chang, MSE, Francis Deng, MD, Brent P. Little, MD, Dexter P. Mendoza, MD, Min Lang, MD, MSc, Susanna I. Lee, MD, PhD, Aileen O'Shea, MD, Anushri Parakh, MD, Praveer Singh, PhD, Jayashree Kalpathy-Cramer, PhD*. (2020). Automated Assessment and Tracking of COVID-19 Pulmonary Disease Severity on Chest Radiographs using Convolutional Siamese Neural Networks. *Radiology: Artificial Intelligence*.
36. Li, Q., Zhang, J., Ling, Y., Li, W., Zhang, X., Lu, H., & Chen, L. (2020). A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. *Infection*, 48(4), 577-584. doi:10.1007/s15010-020-01446-z
37. Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., . . . China Medical Treatment Expert Group for, C. (2020). Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med*, 180(8), 1081-1089. doi:10.1001/jamainternmed.2020.2033
38. Liu, Y. P., Li, G. M., He, J., Liu, Y., Li, M., Zhang, R., . . . Diao, B. (2020). Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study. *Ann Transl Med*, 8(10), 635. doi:10.21037/atm-20-2372
39. Matos, J., Paparo, F., Mussetto, I., Bacigalupo, L., Veneziano, A., Perugin Bernardi, S., . . . Rollandi, G. A. (2020). Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome. *Eur Radiol Exp*, 4(1), 39. doi:10.1186/s41747-020-00167-0
40. McRae, M. P., Simmons, G. W., Christodoulides, N. J., Lu, Z., Kang, S. K., Fenyo, D., . . . McDevitt, J. T. (2020). Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19. *Lab Chip*, 20(12), 2075-2085. doi:10.1039/d0lc00373e
41. Myrstad, M., Ihle-Hansen, H., Tveita, A. A., Andersen, E. L., Nygard, S., Tveit, A., & Berge, T. (2020). National Early Warning Score 2 (NEWS2) on admission predicts

severe disease and in-hospital mortality from Covid-19 - a prospective cohort study.

Scand J Trauma Resusc Emerg Med, 28(1), 66. doi:10.1186/s13049-020-00764-3

42. Laguna-Goya, R., Utrero-Rico, A., Talayero, P., Lasa-Lazaro, M., Ramirez-Fernandez, A., Naranjo, L., . . . Paz-Artal, E. (2020). IL-6-based mortality risk model for hospitalized patients with COVID-19. *J Allergy Clin Immunol*, 146(4), 799-807 e799. doi:10.1016/j.jaci.2020.07.009
43. Satici, C., Demirkol, M. A., Sargin Altunok, E., Gursay, B., Alkan, M., Kamat, S., . . . Esatoglu, S. N. (2020). Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. *Int J Infect Dis*, 98, 84-89. doi:10.1016/j.ijid.2020.06.038
44. Shang, Y., Liu, T., Wei, Y., Li, J., Shao, L., Liu, M., . . . Wang, X. (2020). Scoring systems for predicting mortality for severe patients with COVID-19. *EClinicalMedicine*, 24, 100426. doi:10.1016/j.eclinm.2020.100426
45. Shashikumar, P., Gabriel Wardi MD, MPH, Paulina Paul, MS, Morgan Carlile, MD, Laura N Brenner, MD, Kathryn A Hibbert, MD, Crystal M. North, MD, MPH, Shibani S. Mukerji, MD, Gregory K. Robbins, MD, MPH, Yu-Ping Shao, MS, Atul Malhotra, MD, M. Brandon Westover, MD, PhD, Shamim Nemati, PhD. (2020). Development and Prospective Validation of a Transparent Deep Learning Algorithm for Predicting Need for Mechanical Ventilation. doi:10.1101/2020.05.30.20118109.this
46. Singh, K., MMSc, Thomas S. Valley, MD, MSc, Shengpu Tang, BSE, Benjamin Y. Li, BS, Fahad Kamram, BA, Michael W. Sjoding, MD, Jenna Wiens, PhD, Erkin Otles, MEng, John P. Donnelly, PhD, Melissa Y. Wei, MD, MPH, MS, Jonathon P. McBride, BS, Jie Cao, MPH, Carleen Penzoza, MHSA, RN, John Z. Ayanian, MD, MPP, Brahmajee K. Nallamothu, MD, MPH. (2020). Evaluating a Widely Implemented Proprietary Deterioration Index Model Among Hospitalized COVID-19 patients. doi:10.1101/2020.04.24.20079012.this
47. Sun H.*, A. J., Michael J. Leone*, Haitham S. Alabsi, Laura Brenner, Elissa Ye, Wendong Ge, Yu-Ping Shao, Christine Boutros, Ruopeng Wang, Ryan Tesh, Colin Magdamo, Sarah I. Collens, Wolfgang Ganglberger, Ingrid V. Bassett, James B. Meigs, Jayashree Kalpathy-Cramer, Matthew D. Li, Jacqueline Chu, Michael L. Dougan, Lawrence Stratton, Jonathon Rosand, Bruce Fischl, Sudeshna Das, Shibani Mukerji**,

- Gregory K. Robbins**, M. Brandon Westover**. (2020). COVID-19 Outpatient Screening: a Prediction Score for Adverse Events. doi:10.1101/2020.06.17.20134262.this
48. Sun, L., Song, F., Shi, N., Liu, F., Li, S., Li, P., . . . Shi, Y. (2020). Combination of four clinical indicators predicts the severe/critical symptom of patients infected COVID-19. *J Clin Virol*, 128, 104431. doi:10.1016/j.jcv.2020.104431
49. Wang, B., Zhong, F., Zhang, H., An, W., Liao, M., & Cao, Y. (2020). Risk Factor Analysis and Nomogram Construction for Non-Survivors among Critical Patients with COVID-19. *Jpn J Infect Dis*, 73(6), 452-458. doi:10.7883/yoken.JJID.2020.227
50. Wang, K., Zuo, P., Liu, Y., Zhang, M., Zhao, X., Xie, S., . . . Liu, C. (2020). Clinical and Laboratory Predictors of In-hospital Mortality in Patients With Coronavirus Disease-2019: A Cohort Study in Wuhan, China. *Clin Infect Dis*, 71(16), 2079-2088. doi:10.1093/cid/ciaa538
51. Wei, W., Hu, X. W., Cheng, Q., Zhao, Y. M., & Ge, Y. Q. (2020). Identification of common and severe COVID-19: the value of CT texture analysis and correlation with clinical characteristics. *Eur Radiol*, 30(12), 6788-6796. doi:10.1007/s00330-020-07012-3
52. Wu, Q., Wang, S., Li, L., Wu, Q., Qian, W., Hu, Y., . . . Tian, J. (2020). Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19. *Theranostics*, 10(16), 7231-7244. doi:10.7150/thno.46428
53. Wu, S., Du, Z., Shen, S., Zhang, B., Yang, H., Li, X., . . . Huang, J. (2020). Identification and validation of a novel clinical signature to predict the prognosis in confirmed COVID-19 patients. *Clin Infect Dis*. doi:10.1093/cid/ciaa793
54. Xiao, L. S., Zhang, W. F., Gong, M. C., Zhang, Y. P., Chen, L. Y., Zhu, H. B., . . . Zhu, H. (2020). Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019. *EBioMedicine*, 57, 102880. doi:10.1016/j.ebiom.2020.102880
55. Yadaw, A., Yan-chak Li, MPhil, Sonali Bose, MD, MPH, Ravi Iyengar, PhD, Supinda Bunyavanich, MD, MPH, MPhil, and Gaurav Pandey, PhD. (2020). Clinical Predictors of COVID-19 mortality. doi:10.1101/2020.05.19.20103036.this
56. Zhang, S., Guo, M., Duan, L., Wu, F., Hu, G., Wang, Z., . . . Jin, Y. (2020). Development and validation of a risk factor-based system to predict short-term survival in adult

- hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. *Crit Care*, 24(1), 438. doi:10.1186/s13054-020-03123-x
57. Zheng, Y., Xiao, A., Yu, X., Zhao, Y., Lu, Y., Li, X., . . . Yin, B. (2020). Development and Validation of a Prognostic Nomogram Based on Clinical and CT Features for Adverse Outcome Prediction in Patients with COVID-19. *Korean J Radiol*, 21(8), 1007-1017. doi:10.3348/kjr.2020.0485
58. Zheng, Y., Zhang, Y., Chi, H., Chen, S., Peng, M., Luo, L., . . . Wang, D. (2020). The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study. *Clin Chem Lab Med*, 58(7), 1106-1115. doi:10.1515/cclm-2020-0377
59. Zhou, Y., He, Y., et al. Development and validation a nomogram for predicting the risk of severe COVID-19: A multi-center study in Sichuan, China. *PLoS ONE*. 2020; 15(5):1-13. Doi:10.1371/journal.pone.0233328

Supplemental file 1. Search terms for PubMed.

1.

Risk Factors"[Mesh] OR "Prognosis"[Mesh] OR "ROC Curve"[Mesh] OR "Severity of Illness Index"[Mesh] OR "Hospitalization"[Mesh] OR "Forecasting"[Mesh] OR "Intubation, Intratracheal"[Mesh] OR "Respiration, Artificial"[Mesh] OR "Multiple Organ Failure"[Mesh] OR "Heart Failure"[Mesh] OR "Renal Insufficiency"[Mesh] OR "Diabetic Ketoacidosis"[Mesh] OR "Brain Diseases"[Mesh] OR "Endocrine System Diseases"[Mesh] OR predict*[Title] OR clinical score[Title/Abstract] OR risk score[Title/Abstract] OR disease severity[Title/Abstract] OR mortality[Title] OR mechanical ventilation[Title/Abstract] OR organ failure[Title/Abstract] OR heart failure[Title/Abstract] OR renal failure[Title/Abstract] OR endocrinopathy[Title/Abstract] OR encephalopathy[Title/Abstract] OR intubation[Title/Abstract]

2.

covid[Title/Abstract] OR covid19 [Title/Abstract] OR coronavirus2 [Title/Abstract] OR corona virus 2 [Title/Abstract] OR coronavirus 2 [Title/Abstract] OR corona virus 2 [Title/Abstract] OR SARS COV2 [Title/Abstract] OR SARS COV 2[Title/Abstract] OR 2019 nCoV infection[Title/Abstract] OR HCOV [Title/Abstract] OR Wuhan seafood market pneumonia

virus[Title/Abstract] OR wuhan coronavirus [Title/Abstract] OR "COVID-19" [Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept] OR "Coronavirus Infections"[Mesh:NoExp] OR "Coronavirus"[Mesh:NoExp]

3.

"Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh])

4.

"Letter" [Publication Type] OR "Editorial" [Publication Type] OR "Comment" [Publication Type] OR "Review" [Publication Type]

#1 AND #2 NOT (#3 OR #4)= 2896, limited to english[Filter] AND 2020:2020[pdat]

Table 1. Data Summary

First Author	Type of Study	Outcome	Prediction Model	Sample Size	Type of validation	Performance (AUC)	Location
Al-Najjar H et al. ¹⁸	Retrospective	Death	Country, infection reason, sex, group, confirmation date, birth year, and region	659	Split	.908 for recovery, .985 for death	Korea
Bae J et al. ¹⁹	Retrospective	Mechanical ventilation, death	Chest X-Ray (deep learning)	514	Split	.904 for ventilation .936 for mortality	US
Bahl et al. ²⁰	Retrospective	Death	Age, RR, SpO2, Cr, ALT, procalcitonin, lactic acid	1629	LOOCV	V 0.80	US
Bello-Chavolla, O. Y. et al. ²¹	Retrospective	Death	Age, diabetes, diabetes, obesity, CKD, hypertension, and immunosuppression	177 133	Split	V .823	Mexico
Bi X et al. ²²	Retrospective	Severe case	Fibrinogen to albumin ratio, platelet	141	External validation	V .754	China
Borghesi A et al. ²³	Retrospective	Death	Brixia score, age, immunosuppression	302	External validation	V .853	Italy
Chen R et al. ²⁴	Retrospective	Death	Age, CHD, CVD, dyspnea, procalcitonin, AST	1590	Bootstrap	V .91 (95% CI, .85-.97)	China
Chen A et al. ²⁵	Retrospective	Death	BUN, D-dimer	305	Bootstrap	V 0.929	China
Cheng F et al. ²⁶	Retrospective	ICU	RR, WBC, Lymphocyte, DBP, CRP, SpO2, age, temp, pulse, QRS duration, BUN, sodium, T wave axis, anion gap, SBP, PR interval, R wave axis, RBC, Calcium, Albumin	1987	Split	V .799 (95% CI: .752-.846)	US
Clift A et al. ¹⁴	Retrospective	Death	age, ethnicity, deprivation, BMI, comorbidity	8256158	Two temporary validations	V 0.928 (0.919 to 0.938)	UK

Dong Y et al. ²⁷	Retrospective	Death	HTN, neutrophil to lymphocyte, and NT-Pro BNP	628	Split	V 0.922 (14day), V 0.881 (21 day)	China
Galloway J et al. ²⁸	Retrospective	ICU, death	age, male, non-white ethnicity, SpO2, radiological severity score>3, neutrophil count, CRP, albumin, Cr, diabetes, hypertension and chronic lung disease	1157	Split	V .714 (95%CI .665, .762)	UK
Gong J et al. ²⁹	Retrospective	Severe case	Age; LDH, CRP, RDW, BUN, and direct bilirubin; and albumin	372	Split	V .853 (95% CI, .790-.916)	China
Haimovich et al. ³⁰	Retrospective	Respiratory failure	Quick COVID severity index (RR, SpO2, and O2 flow rate), COVID severity score (O2 flow, SpO2, AST, Chloride, Procalcitonin, RR, SBP, ALT, WBC, BUN, Glucose, CRP, Ferritin, age, Cr)	1792	10-fold cross validation	V.81 (95% CI.73, .89) for the quick COVID severity index, V 0.76 [95% CI 0.65 to 0.86] for COVID severity score	US
Hu H et al. ³¹	Retrospective	Death	Rapid Emergency Medicine Score (REMS)	138	External	V 0.833 (95% confidence interval [CI] = 0.737 to 0.928)	China
Jang JG et al. ³²	Retrospective	Death and critical outcomes	SIRS, qSOFA, NEWS	110	External	V SIRS = .639 (95% CI, .423-.856) qSOFA = .779 (95% CI, .600-.957) NEWS = 0.867 (95% CI .709-1.000) for mortality, SIRS = .744 (95% CI, .602-.886), qSOFA = .760 (95% CI, .620-.899), and NEWS = .918 (95%	Korea

						CI, .841–.995) for critical outcomes	
Ji D et al. ³³	Retrospective	Severe case	Age, comorbidity, lymphocyte, LDH	208	bootstrap	V .91 (95% CI, .86-.94)	China
Knight et al. ¹²	Retrospective	Death	age, sex, comorbidities, RR, SpO2, level of consciousness, BUN, and CRP	57824	Split	V range .767 (95%CI .760, .773)	UK, Wales, Ireland
Li M et al. ³⁴	Retrospective	Mechanical ventilation, death	Pulmonary X ray severity score	263	External	V .80 (95%CI .75-.85)	US
Li Q et al. ³⁵	Retrospective and prospective	Severe disease	Age, LDH, CD4	639	Prospective	V .92	China
Liang W et al. ³⁶	Retrospective	Mechanical ventilation, death, ICU	chest radiographic abnormality, age, hemoptysis, dyspnea, unconsciousness, number of comorbidities, cancer history, neutrophil-to-lymphocyte ratio, LDH and direct bilirubin.	2300	Split	D .88 (95% CI, .85-.91) V .88 (95% CI, .84-.93)	China
Liu Y et al. ³⁷	Retrospective	Severe/Critical illness	Neutrophil to lymphocyte ratio, CRP	84	Split	D .804 (95% CI: .702-.883), V .881 (95% CI: .782-.946)	China
Matos J et al. ³⁸	Prospective	Mechanical ventilation, death	Gender, chronic lung disease, duration of symptom, predominant type, WBC count, aortic and coronary calcification, comorbidity, lymphocyte, age, volume of disease, CRP	106	Cross validation	V 0.92	Italy
McRae et al. ³⁹	Prospective	Death	biomarkers (cTnI, PCT, MYO, and CRP), age, and sex	172	External validation	V 0.94 (0.89–0.99)	China

Myrstad et al. ⁴⁰	Prospective	Severe disease	NEWS2 score $\geq$ 6	66	External validation	V .822, (95% CI .690-.953)	Norway
Laguna-Goya et al. ⁴¹	Prospective	Death	SpO ₂ /FiO ₂ ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age	611	bootstrap	V.93	Spain
Satici C et al. ⁴²	Retrospective	Death	PSI, CRP	681	External validation	V .92 (95% CI .89-.94)	Turkey
Shang Y et al. ⁴³	Retrospective	Death	Age, CVD, lymphocytes, Procalcitonin and D-dimer	452	External validation	V .938(95%CI .902-.973)	China
Shashikumar SP et al. ^{*44}	Retrospective and prospective	Intubation	Deep learning [#]	777	External validation	V.918	US
Singh K et al. ^{*45}	Retrospective	Death, ICU, intubation	Epic deterioration index	174	External validation	V0.67 (95% CI 0.59-0.75)	US
Sun H et al. ^{*46}	Retrospective and prospective	Hospitalization, critical illness, death	CoVAS model [§]	11,586	Cross validation and External	Hospitalization V.76, critical illness V.79, death V.93	US
Sun L et al. ⁴⁷	Retrospective	Severe and critical symptoms	age, GSH, CD3 percentage and total protein	336	Not specified	D 0.9997 and V 0.9757	China
Wang B et al. ⁴⁸	Retrospective	Death	Age, Chest tightness, AST, BUN	104	Bootstrap	V.893 (95% CI, .807-.980)	US
Wang K et al. ⁴⁹	Retrospective	Death	Age, HTN, CAD (clinical) Age, CRP, SpO ₂ , Neutrophil, Lymphocyte, d-dimer, AST, GFR (lab based)	340	Split	Clinical V .83 (95%CI .68-.93), Lab V .88 (95%CI .75-.96)	China
Wei W et al. ⁵⁰	Retrospective	Severe COVID-19	CT score, CD8, CRP, tight chest	81	LGOCV	Clinical D.97 V.90 Radiomics D.95 V.89	China

Wollenstein-Betech S* et al. ¹⁵	Retrospective	1)Hospitalization, 2)death, 3)ICU, 4)mechanical ventilation	1)age, gender, CKD, diabetes, immunosuppression, 2) age, SARS-CoV-2 test, immunosuppression and pregnancy, 3)pneumonia, CVD, asthma, and SARS-CoV-2 test, 4)ICU and pneumonia, age, gender, CVD, obesity, pregnancy, and SARS-CoV-2 test	91,179	Cross validation	1).612-.622 2).674-.687 3).538-.554 4).541-.560	Mexico
Wu G et al. ¹³	Retrospective	Severe or critical illness	Age, Lymphocytes, CRP, LDH, CK, BUN, Ca, Total protein	725	Prospective validation	V range of .84 to .93	China, Italy, Belgium
Wu Q et al. ⁵¹	Retrospective	death, mechanical ventilation, ICU	clinic-radiomics signature (CrrScore) early/late phase	492	Split	Early phase D .826 (.714-.937), V .850 (.763-.935), Late phase D .911 (.796-.999), V .886 (.675-.999)	China
Wu S et al. ⁵²	Retrospective	Severe COVID-19	Age, neutrophil, lymphocyte, procalcitonin, and C-reactive protein	270	Split	D .955 V .945	China
Xiao, S. et al. ⁵³	Retrospective	Severe case	Hypertension, Neutrophil, CRP, Lymphocyte, LDH	690	Internal and external validation	V .871, 95% CI: .769-.972 (Internal), V .826, 95% CI: .746-.907 (external)	China
Yadaw A et al.* ⁵⁴	Retrospective and prospective	Death	Age, SpO2, type of encounter, hydroxychloroquine, and max temperature	5051	External	V .91	US
Zhang C et al. ³	Retrospective	Severe COVID-19	Age, WBC, Neutrophil, GFR, Myoglobin	80	Scoring validated internally	V .906	China
Zhang S et al. ⁵⁵	Retrospective	Death	Age, LDH, Neutrophil to lymphocyte, and bilirubin	828	External	V #1 .878, #2 .839	China

Zheng Y et al. ⁵⁶	Retrospective	Composite outcome ICU, mechanical ventilation, death Secondary Death	Age, sex, comorbidity, lymphocyte, extent, crazy paving sign, change in liver density	238	Split	V .89 (95% CI, .82–.96)	China
Zheng Y et al. ⁵⁷	Retrospective	Severe COVID-19	Neutrophil, Lymphocytes, and Platelets (NLP score)	141	Validation with survival nomogram	V .821 (95% CI, .746–.896)	China
Zhou Y et al. ⁵⁸	Retrospective	Severe COVID-19 per ATS guidelines	temperature, cough, dyspnea, HTN, CVD, CLD, and CKD	366	bootstrapping	Derivation.86 Validation.84 Nomogram .86	China

*Preprint only, # Deep learning model does not give an importance of variables for prediction. \$ Model variables include age, diastolic BP, SpO2, Positive COVID, respiratory rate, stroke, chest x ray finding, heart rate, temperature, systolic BP, Charlson score, intracranial hemorrhage, subarachnoid hemorrhage, male, hematologic malignancy, renal cancer, pancreatitis, cystic fibrosis, cardiac arrest, seizure, amyolateral sclerosis, metabolic acidosis, myasthenia gravis, pneumothorax, spinal muscular dystrophy, pericarditis, high or low BMI, ARDS. D: Derivation AUC, V: Validation AUC.

Table 2. A list of studies with low risk of bias and low concern for applicability

First Author	Outcome	Predictors	Performance (AUC)	Metrics	Setting	Geographic location	Online Risk Calculator
Clift A et al. ¹⁴	Death, Hospitalization	Age, Sex, Ethnicity, BMI, postal (zip) code, housing, comorbidity	0.928, second validation 0.776	Absolute risk and relative risk	General	UK	https://qcovid.org/BMJ/
Knight S et al. ¹²	Death	Age, sex, comorbidity, respiratory rate, SpO2, GSC, BUN, CRP	0.767 (0.760 to 0.773)	Probability	Hospital	UK, Wales, Ireland	https://isaric4c.net/risk

PRISMA 2009 Flow Diagram

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Figure 2. Risk of Bias and Concern for Applicability

Figure 3. Risk of Bias and Concern or Applicability

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.